Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABLTS:0GRZ +2.37%93 FCF Margin % is 25.74% as of Jun. 2026, which is 98% above its 10-year median of 12.98. GuruFocus rates LTS:0GRZ with a GF Score™ of 93/100 and a GF Value™ of kr188.22 (Fairly Valued). The stock has 2 warning signs investors should review. Among 665 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 81.65% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's FCF Margin % or its related term are showing as below:
LTS:0GRZ'
s FCF Margin % Range Over the Past 10 Years
Min: -7.2 Med: 12.98 Max: 24.13
Current: 13.2
During the past 13 years, the highest FCF Margin % of RaySearch Laboratories AB was 24.13%. The lowest was -7.20%. And the median was 12.98%.
LTS:0GRZ's FCF Margin % is ranked better than 81.65% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 3.15
vs LTS:0GRZ: 13.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GRZ vs VEEV, BTSG, HQY: FCF Margin % Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (LTS:0GRZ) has a FCF Margin % of 25.74% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RaySearch Laboratories AB and its competitors. This is 98% above median its historical median of 12.98. According to the industry distribution chart, RaySearch Laboratories AB ranks #122 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 18.3%.
Is RaySearch Laboratories AB's FCF Margin % too high?
RaySearch Laboratories AB's current FCF Margin % of 25.74% is 98% above median its 10-year median of 12.98. The Healthcare Providers & Services industry median FCF Margin % is 3.15. RaySearch Laboratories AB's value of 25.74% is 717.1% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #122 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's FCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #122 out of 665 companies for FCF Margin %. This places RaySearch Laboratories AB in the top 18% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.15. RaySearch Laboratories AB's value of 25.74% is 717.1% above this benchmark. While the company's 10-year median is 12.98 vs. the industry median of 3.15, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.15, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current FCF Margin % of 25.74% is 717.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current FCF Margin % is 25.74%, which is 98% above median its own 10-year median of 12.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (LTS:0GRZ) is currently considered Fairly Valued. The stock's GF Value™ is kr188.22, compared to a current price of kr194.65 — trading 3.4% above its estimated fair value. The current FCF Margin % is 25.74%, which is 98% above median its 10-year median of 12.98 and 717.1% above the Healthcare Providers & Services industry median of 3.15. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For RaySearch Laboratories AB (LTS:0GRZ), the current FCF Margin % is 25.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (LTS:0GRZ) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr194.65 is trading 3.4% above its estimated GF Value™ of kr188.22.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for LTS:0GRZ:
FCF Margin %: 25.74% (98% above median its 10-year median of 12.98)
GF Value™: kr188.22 vs. price of kr194.65 (3.4% above fair value)
Industry Position: 717.1% above the Healthcare Providers & Services median (#122 of 665)
No single metric tells the full story. See the LTS:0GRZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for LTS:0GRZ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GRZ has been successfully added to your 
